{"filing":{"accession_number":"0001437749-26-028111","cik":"0001719406","ticker":"NRXPW","company_name":"NRX Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-08-17","report_date":"2026-08-17","primary_document":"nrxp20260817_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1719406/000143774926028111/nrxp20260817_8k.htm"},"events":[{"id":28111,"run_id":25693,"accession_number":"0001437749-26-028111","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"NRx Pharmaceuticals disclosed its second quarter 2026 financial results via press release on August 17, 2026, as required under Item 2.02. The filing reports net loss of $18.0 million for the six months ended June 30, 2026 (versus $23.1 million in the prior year), net operating loss of $11.3 million, and cash position of $26.7 million as of June 30, 2026. The press release is attached as Exhibit 99.1 and constitutes a standard quarterly earnings announcement.","company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXPW","filing_date":"2026-08-17","form":"8-K","submitted_at":null,"items":[{"id":29919,"accession_number":"0001437749-26-028111","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"NRx Pharmaceuticals disclosed its second quarter 2026 financial results via press release on August 17, 2026, as required under Item 2.02. The filing reports net loss of $18.0 million for the six months ended June 30, 2026 (versus $23.1 million in the prior year), net operating loss of $11.3 million, and cash position of $26.7 million as of June 30, 2026. The press release is attached as Exhibit 99.1 and constitutes a standard quarterly earnings announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T12:03:45.151392+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29919,"accession_number":"0001437749-26-028111","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"NRx Pharmaceuticals disclosed its second quarter 2026 financial results via press release on August 17, 2026, as required under Item 2.02. The filing reports net loss of $18.0 million for the six months ended June 30, 2026 (versus $23.1 million in the prior year), net operating loss of $11.3 million, and cash position of $26.7 million as of June 30, 2026. The press release is attached as Exhibit 99.1 and constitutes a standard quarterly earnings announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-17T12:03:45.151392+00:00","company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXPW","filing_date":"2026-08-17"}]}